

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2024

(Rs. in Lakhs)

| | Particulars | 3 months ended | Preceding 3 | Corresponding | Year ended |
|---|---|----------------|----------------|----------------|---------------|
| | | 30.06.2024 | months ended | 3 months ended | 31.03.2024 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | | | (Refer Note 2) | | |
| | Income | | | | |
| 1 | Revenue from operations | 81465 | 92980 | 76166 | 345371 |
| 2 | Other income | 3564 | 2983 | 3644 | 12259 |
| 3 | Total Income (1+2) | 85029 | 95963 | 79810 | 357630 |
| | Expenses | | | | |
| | (a) Cost of materials consumed | 13823 | 20460 | 15841 | 54517 |
| | (b) Purchases of stock-in-trade | 17274 | 25574 | 17420 | 85308 |
| | (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | (1570) | (9321) | (3649) | (6372) |
| | (d) Employee benefits expense | 15128 | 17283 | 16500 | 62439 |
| | (e) Finance costs | 37 | 77 | 28 | 180 |
| | (f) Depreciation and amortisation expense | 1641 | 1810 | 1636 | 6968 |
| | (g) Other expenses | 13756 | 13258 | 15666 | 58610 |
| 4 | Total expenses | 60089 | 69141 | 63442 | 261650 |
| 5 | Profit before exceptional items and tax (3-4) | 24940 | 26822 | 16368 | 95980 |
| 6 | Exceptional items [credit/ (charge)] (Refer Note 4) | - | 240 | 1730 | (14361) |
| 7 | Profit before tax (5+6) | 24940 | 27062 | 18098 | 81619 |
| 8 | Tax expense | | | | |
| | (a) Current tax | 6356 | 6167 | 5323 | 23759 |
| | (b) Deferred tax | 351 | 1447 | (450) | (1136) |
| 9 | Profit for the period/year (7-8) | 18233 | 19448 | 13225 | 58996 |

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2024

(Rs. in Lakhs)

| | Particulars | 3 months ended 30.06.2024 | Preceding 3 months ended 31.03.2024 | Corresponding 3 months ended 30.06.2023 | Year ended 31.03.2024 |
|----|--|------------------------------|---|---|--------------------------|
| | | (Unaudited) | (Unaudited) (Refer Note 2) | (Unaudited) | (Audited) |
| 10 | Other comprehensive income | | | | |
| | (i) Items that will not be reclassified to profit or loss | - | (91) | - | (557) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | - | 22 | - | 140 |
| 11 | Total comprehensive income for the period (9+10) | 18233 | 19379 | 13225 | 58579 |
| 12 | Total comprehensive income for the period attributable to owners of the Group | 18233 | 19379 | 13225 | 58579 |
| | Paid-up equity share capital (face value per share Rs. 10) | 16941 | 16941 | 16941 | 16941 |
| | Other equity | | | | 160823 |
| | Earnings per share (EPS) (of Rs. 10 each) | | | | |
| | Basic and diluted EPS before Exceptional items (Rs.) | 10.76 | 11.37 | 7.04 | 41.14 |
| | Basic and diluted EPS after Exceptional items (Rs.) | 10.76 | 11.48 | 7.81 | 34.83 |
| | | Not Annualised | | | |

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 02nd August 2024. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June, 2024.
2. The figures for the 3 months ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2024.
3. Dividend of Rs. 32 per equity share for the year ended 31st March 2024 had been approved by the shareholders in the Annual General meeting held on 28th June 2024.
4. Exceptional items pertaining to prior period / year :
 - (a) Exceptional items credit for the quarter ended 30th June 2023 of Rs.1730 lakhs (Quarter ended 31st March 2024 Rs. 240 lakhs) is on account of profit on sale of surplus residential properties.
 - (b) Exceptional items charge for the year ended 31st March 2024 of Rs.14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
5. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

02nd August, 2024

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346